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Background: Recently, histopathological tumour regression, prevalence of signet ring cells, and localisation were reported as
prognostic factors in neoadjuvantly treated oesophagogastric (junctional and gastric) cancer. This exploratory retrospective study
analyses independent prognostic factors within a large patient cohort after preoperative chemotherapy including clinical and
histopathological factors.
Methods: In all, 850 patients presenting with oesophagogastric cancer staged cT3/4 Nany cM0/x were treated with neoadjuvant
chemotherapy followed by resection in two academic centres. Patient data were documented in a prospective database and
retrospectively analysed.
Results: Of all factors prognostic on univariate analysis, only clinical response, complications, ypTNM stage, and R category were
independently prognostic (Po0.01) on multivariate analysis. Tumour localisation and signet ring cells were independently
prognostic only when investigator-dependent clinical response evaluation was excluded from the multivariate model.
Histopathological tumour regression correlates with tumour grading, Laure´n classification, clinical response, ypT, ypN, and
R categories but was not identified as an independent prognostic factor. Within R0-resected patients only surgical complications
and ypTNM stage were independent prognostic factors.
Conclusions: Only established prognostic factors like ypTNM stage, R category, and complications were identified as
independent prognostic factors in resected patients after neoadjuvant chemotherapy. In contrast, histopathological tumour
regression was not found as an independent prognostic marker.
Perioperative chemotherapy for locally advanced oesophagogastric
cancer is a recommended standard of care in Europe (Cunningham
et al, 2006, 2008; Ychou et al, 2011; Lutz et al, 2012). For
adenocarcinomas of the oesophagogastric junction (AEG), neoad-
juvant chemoradiotherapy has been suggested to further improve
response rates and prognosis (Stahl et al, 2009; Burmeister et al,
2011; Sjoquist et al, 2011; van Hagen et al, 2012), although the
5-year survival gain reported in the CROSS study is in the same
range as in the MAGIC (Cunningham et al, 2006) and FFCD
(Ychou et al, 2011) perioperative chemotherapy studies. However,
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the histopathological complete response rates of the CROSS study
and the results in the surgery alone arm were excellent and similar
rates were reached in only a few other randomised controlled
multicentre studies (Hulscher et al, 2002).
The evaluation of prognostic factors within neoadjuvantly
treated patients was mainly performed retrospectively within
phase II studies with limited patient numbers (Lowy et al, 1999;
Becker et al, 2003; Mansour et al, 2007; Fujitani et al, 2012;
Lorenzen et al, 2012; Koh et al, 2013). The reliability of these
reports is limited by the relatively small sample size of most of
the studies, and by heterogeneity with regard to the patient
cohorts, to neoadjuvant treatment, response evaluation and
histopathological regression (HPR) scoring systems. The factors
included in the respective multivariate analysis strongly affect the
study results and are difficult to compare. Often, ypT category,
ypN category, Laure´n classification, tumour localisation, tumour
differentiation, perineural or vascular invasion, and response were
selected by Cox regression (Lowy et al, 1999; Becker et al, 2003;
Mansour et al, 2007; Fujitani et al, 2012; Lorenzen et al, 2012; Koh
et al, 2013).
Larger series mostly focussed on single prognostic factors of
interest. Special attention was recently paid to three factors:
localisation (Kunz et al, 2012; Lorenzen et al, 2012; Reim et al,
2012), HPR (Langer et al, 2009; Becker et al, 2011), and signet ring
cell cancer (SRC) (Messager et al, 2011; Kunz et al, 2012; Taghavi
et al, 2012). However, most of these factors were not even used for
stratification within clinical trials, because they were judged to be
too weak or too difficult to assess on a standardised basis to enable
stratification to be performed.
Response to neoadjuvant treatment is an important clinical
readout for tumour biology and was first described by Lowy et al.
for gastric adenocarcinomas (Lowy et al, 1999). The focus of this
study is the histopathological tumour regression after chemother-
apy, which was found to be an independent prognostic factor in a
large series with gastric cancer (GC) (Becker et al, 2011). Despite
being considered as the gold standard for response evaluation,
histopathological response is still not clearly defined and several
competing scoring systems associated with prognosis exist
(Kurihara and Aiko, 2001; Mansour et al, 2007; Becker et al,
2011). Most often, patients with o10% residual tumour are
classified as responder (Schneider et al, 2008; Becker et al, 2011;
Lorenzen et al, 2012). But it needs to be noted that about 30% of
patients with an obvious HPR of the primary tumour still die due
to recurrence (Fields et al, 2011; Ott et al, 2013). HPR assessment is
not free of bias and it depends on the experience of the respective
pathologist and the processing of the resection specimens. Given
these limitations, the significance of HPR as an independent
prognostic factor remains unclear. The value of HPR as a
prognostic factor needs to be analysed alongside clinical response,
as clinical response was shown to be prognostic by our group and
others (Lowy et al, 1999; Ott et al, 2003; Weber et al, 2003), but was
deemed to be investigator dependent by other groups (Schneider
et al, 2008).
The aim of our retrospective exploratory study from two
academic centres was the analysis of independent prognostic
factors with special emphasis on influence of HPR, but also
including other factors like clinical response, signet ring cells, and
localisation within a large series of resected oesophagogastric
adenocarcinomas treated with preoperative chemotherapy.
PATIENTS AND METHODS
This retrospective exploratory study includes 850 (of a total of 952)
patients (n¼ 675 Department of Surgery, Klinikum Rechts der
Isar, TU Mu¨nchen and n¼ 175 Department of General, Visceral
and Transplantation Surgery, University of Heidelberg) with
histologically proven locally advanced stage (cT3/4 and cNany)
AEG and GC after neoadjuvant chemotherapy followed by surgical
resection (Figure 1).
Preoperative staging, neoadjuvant chemotherapy, and surgical
therapy. The staging procedures before initiation of chemotherapy
included endoscopy and computed tomography of the chest and
the abdomen. Staging was repeated before resection to determine
clinical response and to exclude distant metastases. The neoadju-
vant chemotherapy was mostly platinum based. Patients under-
went established chemotherapy regimens, including combinations
of platinum (cis- or oxaliplatin) with 5-fluorouracil (or capecita-
bine) either or not combined with anthracyclines (epirubicin) or
taxanes (paclitaxel or docetaxel) (Lim et al, 2003; Bader et al, 2008;
Blank et al, 2013) (Supplementary Table S1).
Surgery. Resection was according to tumour localisation and local
standards (Bader et al, 2008; Ott et al, 2008, 2009; Blank et al, 2013;
Sisic et al, 2013). Tumours of the oesophagogastric junction were
treated by transhiatal extended gastrectomy, abdomino-thoracic
oesophagectomy, or transhiatal oesophagectomy. Gastric cancers
of the middle and distal gastric third were treated with total or
subtotal gastrectomy. All surgical approaches included an abdom-
inal D2 lymphadenectomy.
Histopathological workup and response assessment. The histo-
pathological workup was classified and staged according to the
recommendations by the Union for International Cancer Control
(UICC), 7th edition (UICC, 2010). Histopathological response
was graded according to Becker et al (2003, 2011). Grade 1
response indicates complete or subtotal regression with 1a
complete regression and 1b o10% residual tumour tissue. Grade
2 response indicated partial tumour regression with 10–50%
residual tumour and grade 3 minimal or no tumour regression
(450% residual tumour).
Clinical response evaluation. Clinical response was defined by
the interdisciplinary tumour board based on a combination of
Total patients
collective
(n = 952)
No surgical
resection
(n = 35)
Neoadjuvant
RCTx
(n = 67)
Total patient
undergone resection
(n = 917)
Total patients
with neoadjuvant
chemotherapy
Patients treated at
Munich site
(n = 675)
Patients treated at
Heidelberg site
(n = 175)
Figure 1. Patient collective. Flowchart describing the composition of
the patient collective included in this study.
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endoscopy and CT scan after neoadjuvant treatment before
resection without the knowledge of the histopathological workup.
Responders were defined with at least a partial response (PR) to
both endoscopy (o75% residual tumour) and CT scan (decrease of
450% in the wall diameter) (Ott et al, 2003).
Patient follow-up. The patients were followed up routinely on an
outpatient basis according to a standard protocol with visits q3
month in the first year, q6 month in the second and third year and
yearly afterwards until the end of the fifth year. Patients who did
not participate in this programme were contacted by telephone to
obtain follow-up data.
Statistical analysis. Overall survival was evaluated in months
from time of diagnosis until death or until the most recent follow-
up using the Kaplan–Meier method. Differences in the survival
curves were evaluated by log-rank test for significance. Quantita-
tive values are expressed as mean±standard deviation, median,
and range, and categorical values with absolute and relative
frequencies (count and percent). w2 test was used for comparison of
frequencies, and Spearman correlation coefficients were calculated
to quantify bivariate correlation. Stepwise Cox proportional hazard
regression was performed as multivariate analysis with forward
and backward regression models. A P-value of smaller than 0.05
was considered as statistically significant and all statistical tests
were conducted two-sided. IBM SPSS Version 20 (Ehningen,
Germany) was used for analysis.
RESULTS
Patients. The patients had a median age of 57.5 years (range 17–80)
and were predominantly male (n¼ 687 (79.8%)). The tumour was
localised at the oesophagogastric junction (junctional cancer) in 610
and in the stomach in 240 patients. Further patients’ characteristics
are presented in detail in Table 1. Clinical response was evaluated in
824 of the 850 patients. In all, 28.6% (236) were classified as
responder (Table 2). The surgical procedures and postoperative
complications are also listed in Table 2. Chemotherapy-associated
tumour regression was evaluated according to the tumour regression
system of Becker. In all, 215 tumours (25.2%) showed a
histopathological response of grade 1a (5.6%) or 1b (19.6%),
whereas the remainder showed minor or no response (Table 2).
The median survival was 37.1 months (95% CI: 31.2–43.0
months). The 30-day mortality rate was 3.2% and the in-hospital
mortality rate 7.9%. Analysing the data according to the time point
of diagnosis, no significant survival differences were observed
within the different time intervals (1: 1987–12/1995; 2: 01/1996–
12/2000; 3: 01/2001–12/2005; and 4: 01/2006–12/2010) (Supple-
mentary Figure S1). The distribution of the surgical procedures
remained similar over the study period, with the only difference
that in earlier time points transhiatal oesophageal resection was
favoured over abdomino-thoracic oesophageal resection (Supple-
mentary Table S2A). The number of resected/analysed lymph
nodes was higher at earlier time points (Supplementary Table S2B)
Prognostic factors. Kaplan–Meier curves analysed by log-rank
test revealed tumour grading, Laure´n classification, SRC (according
to WHO definition), clinical response, total complications, surgical
complications, resection status (R0 vs R1/2), ypTNM stage and
HPR (grade 1a/b vs grade 2/3) and detailed HPR (all grades
separately) (total and surgical complications P¼ 0.005, all others
Po0.001) as prognostic factors by univariate analysis in all
included patients. On the other side, completion of the full planned
chemotherapy regimen, site of treatment (Munich vs Heidelberg),
or chemotherapy regimen (anthracycline-containing vs taxane-
containing vs non-anthracycline-non-taxane-containing) were not
found to be a prognostic factor.
Histopathological regression as a prognostic factor. Histopatho-
logical regression grade was found to be strongly associated with
survival. Patients with tumour regression grade 1 (1aþ 1b) had a
median survival of 92.2 months (CI: median survival not reached).
For patients without regression, median survival was 27.9 months
(95% CI: 24.2–31.6 months) (Figure 2A) (Po0.001). Histopatho-
logical regression based on the four groups (grades 1a, 1b, 2, and 3)
did also significantly discriminate the patients’ prognosis
(Po0.001) (Figure 2B). Histopathological response was signifi-
cantly associated with the preoperative grading (P¼ 0.001) and
Laure´n classification of the tumour (P¼ 0.002). Histopathological
response was correlated with clinical response (Po0.001), but not
with discontinuation of chemotherapy. The postoperative para-
meters of ypT, ypN, and R categories were associated with HPR
(Po0.001), whereas the M category not (Supplementary Table S3).
A more detailed analysis showed that in patients with a
histopathological response of the primary tumour, lymph-node
metastases are relatively frequent in the pathological specimens. In
all, 20.9% (10 out of 48) of the patients with regression grade 1a
and 41.6% (67 out of 161) (Table 3) with grade 1b had lymph-node
metastases as well as distant metastases in 8.3% (4 out of 48) vs
21.1% (34 out of 161) (Supplementary Table S4). In all, 55.7%
(93 out of 161) of the responders with grade 1b had an advanced
T category with yT3 and yT4 and 13.8% (23 out of 167) of those
had tumour infiltration of the surgical resection margins (R1/R2)
(Supplementary Table S4).
Clinical response, localisation, and signet ring cell carcinoma.
The analysis of clinical response showed a significantly better
prognosis for clinical responders vs non-responders (Figure 3A)
(Po0.001). Subgroup analysis showed a significant survival
Table 1. Pretreatment clinicopathologic characteristics of the study
population (n¼ 850)
n (%)
Gender
Male 678 (79.8)
Female 172 (20.2)
Localisation
Oesophagus 610 (71.8)
AEG I 241 (28.4)
AEG II 254 (29.9)
AEG III 115 (13.5)
Gastric 240 (28.2)
Gastric body 94 (11.1)
Gastric antrum 94 (11.1)
Total gastric carcinoma 52 (6.1)
Gradinga
G1/2 217 (25.9)
G3/4 621 (74.1)
Laure´n classificationa
Intestinal type 436 (52.3)
Non-intestinal type 397 (47.7)
Signet ring cell cancera
Yes 221 (30.0)
No 516 (70.0)
Abbreviation: AEG¼ adenocarcinomas of the oesophagogastric junction.
aMissing data in some cases.
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difference for patients with a PR (median survival: not reached),
minor response (MR) (median survival: 29.1 months, 95% CI:
22.1–36.1 months), no change (NC) (median survival: 27.1
months, 95% CI: 23.0–32.2 months), and progressive disease
(PD) (median survival: 10.5 months, 95% CI: 9.1–11.9 months)
(Figure 3B).
Also the tumour localisation was found to be a significant
prognostic marker. Patients with a carcinoma involving the entire
stomach had a worse prognosis, whereas all other localisations had
a similar survival (Figure 3C).
When analysing the patients for signet ring cell carcinoma vs
non-signet ring cell carcinoma, it was found that patients with
signet ring cell carcinoma (median survival: 26.7 months, 95% CI:
22.1–31.4 months) had a significantly worse survival than non-
signet ring cell type carcinoma patients (median survival: 46.6
months, 95% CI: 37.9–55.2 months) (Figure 3D, Po0.001).
Analysing only the 637 R0-resected patients by log-rank tests
revealed comparable results for prognostic factors with significant
differences for tumour location, tumour grading, Laure´n classifica-
tion, SRC, clinical response, total complications, surgical complica-
tions, ypTNM, and HPR (grade 1a/b vs grade 2/3).
Independent prognostic factors. Multivariate analysis with Cox
forward and backward regression revealed clinical response, total
complications, and ypT and ypN categories as independent
prognostic factors. M and R categories were independent
prognostic factors in Cox forward regression, but not confirmed
in backward regression. HPR was not confirmed as an independent
prognostic factor neither included as parameter responder vs
non-responder nor with the detailed regression classification
(Table 4A). In the next step clinical response was deleted, because
it is not a generally accepted prognostic factor within all working
groups, because it is judged to be investigator dependent. Without
clinical response Cox regression revealed tumour location, SRC,
total complications, and ypTNM and R categories as independent
prognostic markers in forward and backward Cox regression, again
not HPR (Table 4B). Despite tumour localisation was statistically
significant, the survival curves are crossing (Figure 3C). Therefore,
this parameter was deleted from further analysis. Then in
multivariate analysis, total complications, and ypTNM and R
categories remained as independent prognostic factors (Table 4C).
By multivariate Cox regression analysis (forward and backward
regression), surgical complications and ypTNM categories were
identified as independent prognostic factors (all Po0.005) in the
completely resected patients (Table 4D). As expected distant
metastasis (M1 status) was a prognostic factor, therefore Cox
regression analysis was also performed for all patients without
distant metastasis (M0) (Supplementary Table S5A) and all
curatively resected patients with complete resection (R0) and
without distant metastasis (M0) (Supplementary Table S5B). In
these patient groups, localisation, clinical response, and ypTN
categories remained as independent prognostic factors, whereas
HPR was not found to be statistically significant.
DISCUSSION
This study shows that established prognostic factors like ypTNM
and R categories, as well as complications, are independent
prognostic factors in neoadjuvant treated oesophagogastric adeno-
carcinomas. Hence, similar factors were also revealed to be
prognostically relevant for primary resected tumours. Chemother-
apy-associated characteristics such as histopathological response
scoring were shown to be less important. Even patients with a good
response in their primary tumour often have high T categories and
lymph-node metastases, which may be responsible for the lower
relevance of the tumour regression score in multivariate analysis.
Only one localisation influences outcome in our analysis:
carcinomas of the entire stomach have a disastrous prognosis
compared with all other localisations (Messager et al, 2011;
Lorenzen et al, 2012).
Limitations in other studies are usually related to the inclusion
of only a few preselected parameters. Additionally, differences in
survival over the study period can be observed (Kunz et al, 2012).
In general, it needs to be noted that only a few prospective randomised
Table 2. Post-treatment-related clinical characteristics of the study
population (n¼850)
n (%)
Clinical response
Responder 236 (28.6)
Non-responder 590 (71.4)
Minor response 298 (36.1)
No change 267 (32.3)
Progressive disease 25 (3.0)
Surgical procedure
Abdomino-thoracic oesophageal resection 201 (23.6)
Transmediastinal oesophageal resection 88 (10.4)
Oesophago-gastrectomy 9 (1.1)
Transhiatal extended gastrectomy 295 (34.7)
Total gastrectomy 208 (24.5)
Subtotal gastrectomy 35 (4.1)
Others 14 (1.6)
Complications
Yes 352 (41.5)
Surgical 135 (15.9)
Medical 282 (33.2)
ypT category
ypT0 48 (5.6)
ypT1 62 (7.3)
ypT2 101 (11.9)
ypT3 505 (59.4)
ypT4 134 (15.8)
ypN category
ypN0 314 (37.3)
ypN1 147 (17.5)
ypN2 146 (17.3)
ypN3 235 (27.9)
M category
M0 674 (79.3)
M1 176 (20.7)
R category
R0 637 (74.9)
R1 177 (20.8)
R2 36 (4.2)
HPR
Grade 1a 48 (5.6)
Grade 1b 167 (19.6)
Grade 2 208 (24.5)
Grade 3 427 (50.2)
Abbreviations: HPR¼ histopathological regression; UICC¼Union for International Cancer Control.
TNM classification according to UICC 7th edition.
Prognostic factors in oesophagogastric carcinoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.94 1715
phase III studies exist (Cunningham et al, 2006; Schuhmacher et al,
2010; Ychou et al, 2011) and that the evaluation of prognostic factors
is not a primary objective of phase III studies. Hence, there are
currently some questions that can only be answered retrospectively
(Messager et al, 2011; Kunz et al, 2012), but results must be
interpreted with caution and with the awareness of this limitation.
Considering these limitations, the analysis of our data is more
comprehensive compared with many other published series. We
included a multiplicity of factors such as Laure´n classification,
grading, clinical response, HPR, and SRC classification according
to the WHO. In addition, the clinical information including the
type and conduct of preoperative chemotherapy and intraoperative
Months
Pts at risk 0 12 24 36 48 60 72 84 96 108 120
Responder
Non-resp.
209 165 123 96 68 46 33 22 16 13 6
612 422 247 156 100 66 44 30 20 9 3
Months
Pts at risk 0 12 24 36 48 60 72 84 96 108 120
Grade 1a 48 42 34 25 15 11 10 7 5 4 2
Grade 1b 161 123 89 71 53 35 23 15 11 9 4
Grade 2 200 148 90 65 41 31 24 17 11 4 1
Grade 3 412 274 157 91 49 35 20 13 9 5 2
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Histopathological
regression
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Figure 2. Prognostic value of the histopathological regression. Kaplan–Meier plots for overall survival of (A) histopathological regression
grading grouped grade 1a/b and group 2/3 and (B) histopathological regression by subgrades (n¼ 850, Po0.001). The tables show the number
of patients at risk at the indicated time points.
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and postoperative complications was available. Some other
interesting information, like initial pretherapeutic cTNM
(Messager et al, 2011; Reim et al, 2012), was not completely
recorded in our database and therefore was not included (Blank
et al, 2012). Furthermore, no detailed information on prether-
apeutic performance status or nutritional status was available
(Messager et al, 2011), but all of our patients who were selected for
multimodal treatment had to have a Karnofsky performance status
of 480. Despite prospective meticulous documentation of many
factors, some prognostically relevant factors like lymphangiosis
(von Rahden et al, 2005), perineural or vascular invasion (Mansour
et al, 2007), or tumour regression within the lymph nodes
(Bollschweiler et al, 2011) were only recorded for small subgroups
and were not included in our analysis. As overall survival did not
Table 3. Lymph-node metastasis according to histopathological
regression
Histopathological regression
Lymph-node
metastasis 1a 1b 2 3
Negative 38 (79.2%) 94 (58.4%) 76 (36.7%) 106 (24.9%)
Positive 10 (20.8%) 67 (41.6%) 131 (53.3%) 310 (75.1%)
The table indicates the number of patients with lymph-node metastasis according to
histopathological regression (HPR) as well as the percentage of patients with lymph-node
metastasis for each specific HPR grade.
Months
Pts at risk 0 12 24 36 48 60 72 84 96 108 120
Responder 228 185 134 106 75 52 37 26 19 12 5
570 389 226 138 86 54 36 22 15 8 3
Months
Pts at risk 0 12 24 36 48 60 72 84 96 108 120
PR 228 185 134 106 75 52 37 26 19 12 5
MR 286 202 122 80 51 35 25 17 11 7 3
NC 261 178 99 56 34 19 5 4 1 0 0
PD 25 9 5 2 2 0 0 0 0 0 0
Months
Pts at risk 0 12 24 36 48 60 72 84 96 108 120
AEG I 237 168 105 71 49 35 24 16 12 8 3
AEG II 247 186 122 84 60 38 27 17 11 5 2
AEG III 107 67 39 25 18 12 7 4 3 2 1
G. body 89 66 41 29 18 12 9 7 5 4 2
G. antr. 92 72 48 33 22 15 11 8 6 3 1
Tot. g. 50 29 16 10 3 1 0 0 0 0 0
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Figure 3. Clinical response, localisation, and signet ring cell carcinoma as prognostic factors. Kaplan–Meier plots for overall survival of (A) clinical
response grouped by responders and non-responders, (B) clinical response of partial response (PR), minor response (MR), no change (NC),
progressive disease (PD) and (C) according to tumour localisation of the primary tumour. (A–C, n¼ 850, Po0.001) (D) according to tumour type,
signet ring cell cancer vs non-signet ring cell cancer (n¼ 737, Po0.001). The tables show the number of patients at risk at the indicated time
points.
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change significantly over the study period, inclusion of all patients
over this long time period remains justified.
This study provides important insights into the outcome of
neoadjuvantly treated patients. As a fundamental finding, TNM
classification seems to be the strongest prognostic factor in
neoadjuvantly treated patients, despite being based on the data
from primary resected patients (Gertler et al, 2011; Reim et al,
2013). The prognostic relevance of complications is known in
oesophagogastric adenocarcinoma (Ott et al, 2009; Messager et al,
2011), and was confirmed in our study. Interestingly, for both
groups, the resected and completely (R0) resected patients, the
same prognostic factors were revealed to be significant. Therapy-
associated variables, for example, discontinuation of chemotherapy
or the type of cytotoxic drug combinations applied, were not
statistically relevant or meaningful because of small subgroups and
crossing survival curves.
The inclusion of different localisations of adenocarcinomas as
stratification criterion in studies is a matter of debate because,
according to centres and standards, the associated treatment
strategies might differ significantly. Since our study is focussed on
patients with chemotherapy only, all treated adenocarcinomas were
included according to the MAGIC and FFCD study results
(Cunningham et al, 2006; Ychou et al, 2011). There is an ongoing
discussion regarding whether in AEG I, or even in AEG II and III,
preoperative chemoradiotherapy should be performed (Sjoquist
et al, 2011; van Hagen et al, 2012). In our centres, we mostly used
chemotherapy alone due to the reduced immunosuppression after
chemotherapy compared with radiochemotherapy (Heidecke et al,
2002) and due to the good local resectability of adenocarcinomas
in most cases (Siewert and Ott, 2007). Whether the significantly
higher rates of complete histopathological responses after chemor-
adiotherapy compared with chemotherapy are also translated into
an improved survival remains unclear so far (Vallbohmer et al,
2010; Fields et al, 2011; Ott et al, 2013), as only limited prospectively
controlled randomised data addressing this issue exist (Stahl et al,
2009; Burmeister et al, 2011). In contrast to primary resected AEG
(Siewert et al, 2001), in this study all localisations have a similar
prognosis with only cancers of the entire stomach having a
significantly worse prognosis. This supports our combined analysis
of adenocarcinomas in the upper GI after chemotherapy.
The most remarkable and debatable finding of our retrospective
study was the lack of independent prognostic relevance of the
Table 4. Significant prognostic factors in multivariate analyses
P-value RR 95% CI
(A) (included: localisation, grading, Laure´n classification, signet
ring cell cancer, clinical response, complications, surgical
complications, ypTNM, R status, and histopathological
regression)
Clinical responsea 0.004 1.53 1.14–2.05
Complicationsa 0.001 0.70 0.57–0.87
ypT categorya 0.002
ypT0 0.009 0.31 0.13–0.75
ypT1 0.039 0.51 0.27–0.97
ypT2 o0.001 0.42 0.26–0.68
ypT3 0.140 0.81 0.61–1.07
ypN categorya o0.001
ypN0 o0.001 0.45 0.33–0.63
ypN1 0.010 0.65 0.47–0.90
ypN2 0.003 0.66 0.48–0.68
M category o0.001 0.55 0.42–0.73
R category 0.014
R0 0.018 0.55 0.34–0.91
R1 0.240 0.75 0.47–1.21
(B) (clinical response excluded) (included: localisation, grading,
Laure´n classification, signet ring cell cancer, complications,
surgical complications, ypTNM, R status, and histopathological
regression)
Localisationa 0.006
Signet cell type cancera 0.033 1.32 1.02–1.70
Complicationsa 0.004 0.73 0.58–0.90
ypT categorya o0.001
ypT0 o0.001 0.19 0.08–0.47
ypT1 0.006 0.39 0.20–0.76
ypT2 o0.001 0.38 0.23–0.64
ypT3 0.075 0.73 0.52–1.03
ypN categorya o0.001
ypN0 o0.001 0.40 0.29–0.56
ypN1 0.001 0.57 0.41–0.79
ypN2 o0.001 0.60 0.45–0.80
M categorya o0.001 0.53 0.40–0.70
R categorya 0.009
R0 0.004 0.48 0.29–0.79
R1 0.041 0.60 0.37–0.98
(C) (clinical responseþ localisation excluded) (included: grading,
Laure´n classification, signet ring cell cancer, complications,
surgical complications, ypTNM, R status, and histopathological
regression)
Complicationsa o0.001 0.69 0.56–0.85
ypT categorya o0.001
ypT0 0.001 0.23 0.10–0.55
ypT1 0.008 0.42 0.23–0.80
ypT2 o0.001 0.40 0.28–0.72
ypT3 0.198 0.84 0.64–1.1
ypN categorya o0.001
ypN0 o0.001 0.43 0.32–0.59
ypN1 0.003 0.61 0.44–0.85
ypN2 0.002 0.63 0.47–0.84
M categorya o0.001 0.55 0.42–0.72
R categorya 0.006
R0 0.011 0.53 0.33–0.86
R1 0.212 0.74 0.46–1.19
Table 4. ( Continued )
P-value RR 95% CI
(D) (R0 completely resected patients) (included: grading, Laure´n
classification, signet ring cell cancer, clinical response,
complications, surgical complications, ypTNM, and
histopathological regression)
Surgical complicationsa 0.004 0.68 0.52–0.89
ypT categorya o0.001
ypT0 0.002 0.25 0.10–0.61
ypT1 0.011 0.40 0.19–0.81
ypT2 o0.001 0.36 0.21–0.63
ypT3 0.318 0.922 0.56–1.21
ypN categorya o0.001
ypN0 o0.001 0.39 0.27–0.57
ypN1 0.006 0.58 0.39–0.85
ypN2 0.006 0.59 0.41–0.86
M category a o0.001 0.47 0.33–0.67
Abbreviations: CI¼ confidence interval; RR¼ relative risk.
aConfirmation by Cox backward regression analysis.
Results of Cox forward regression analysis.
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tumour regression score. It was previously shown that about 30%
of patients classified as histopathological responders die due to
recurrence, mostly occurring as distant metastases (Fields et al,
2011; Ott et al, 2013). Here, we found that a relevant percentage of
patients with o10% residual tumour have advanced tumour
categories and/or lymph-node metastases. Although the findings
from the largest series for GC support tumour regression as an
independent prognostic factor (Becker et al, 2011), there are also
other studies in the literature that contradict this finding and thus
support our data (Mansour et al, 2007; Fujitani et al, 2012). We
integrated all pre- and postoperative relevant parameters, including
clinical and histopathological information, as Cox regression
analysis is dependent on the chosen factors. None of the performed
analyses revealed tumour regression as an independent prognostic
factor. Interestingly, clinical response was an independent prog-
nostic factor, but it was excluded from further analysis, because it is
judged to be investigator dependent.
Despite the lack of significance in multivariate analysis,
HPR remains an important piece of information after preoperative
chemotherapy, because it represents an in vivo testing of the
chemosensitivity of the tumour and may serve as a stratification
criterion for tailored postoperative treatment in future studies. Its
clinical relevance must be interpreted with caution, as there are
several classification systems available in the literature (Becker
et al, 2003, 2011; Fujitani et al, 2012), with classification of
responders varying from a complete HPR to o50% residual
tumour (Becker et al, 2003; Mansour et al, 2007; Fujitani et al,
2012). A homogenisation of scoring systems, a standardisation
resection specimen processing, and a consensus definition of a
histopathological response after chemotherapy are strongly
warranted to make study results comparable in the future.
In conclusion, in neoadjuvantly treated oesophagogastric
adenocarcinomas, only established factors such as ypTNM
categories and total complications, and no chemotherapy related
factors, are revealed as independent prognostic factors in our series.
Specifically, HPR was not an independent prognostic factor.
Advanced tumour categories and lymph-node metastases in 440%
of patients with o10% residual tumour might be one reason.
Therefore, since no generally accepted scoring systems exist, HPR
should be interpreted with caution and might be used for
postoperative treatment decisions only in combination with the
established prognostic factors.
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